Academic Journal

Outcomes of Cardiac Resynchronization Therapy in Patients with Hypothyroidism and Heart Failure

التفاصيل البيبلوغرافية
العنوان: Outcomes of Cardiac Resynchronization Therapy in Patients with Hypothyroidism and Heart Failure
المؤلفون: Mei Yang, Xuping Li, John C. Morris, Jinjun Liang, Abhishek J. Deshmukh, David Hodge, Yigang Li, Yong-Mei Cha
المصدر: BMC Cardiovascular Disorders, Vol 20, Iss 1, Pp 1-9 (2020)
بيانات النشر: BMC, 2020.
سنة النشر: 2020
المجموعة: LCC:Diseases of the circulatory (Cardiovascular) system
مصطلحات موضوعية: Diseases of the circulatory (Cardiovascular) system, RC666-701
الوصف: Abstract Background Hypothyroidism is known to be associated with adverse clinical outcomes in heart failure. The association between hypothyroidism and cardiac resynchronization therapy outcomes in patients with severe heart failure is not clear. Methods The study included 1316 patients who received cardiac resynchronization therapy between 2002 and 2015. Baseline demographics and cardiac resynchronization therapy outcomes, including left ventricular ejection fraction, New York Heart Association class, appropriate implantable cardioverter-defibrillator therapy, and all-cause mortality, were collected from the electronic health record. Results Of the study cohort, 350 patients (26.6%) were classified as the hypothyroidism group. The median duration of follow-up was 3.6 years (interquartile range, 1.7–6.2 years). Hypothyroidism was not associated with a higher risk of all-cause mortality in patients receiving CRT for heart failure. The risk of appropriate implantable cardioverter-defibrillator therapy significantly increased in association with increased baseline thyroid-stimulating hormone level in the entire cohort (hazard ratio, 1.23 per 5mIU/L increase; 95% CI, 1.01–1.5; P = 0.04) as well as in the hypothyroid group (hazard ratio, 1.44 per 5mIU/L increase; 95% CI, 1.13–1.84; P = 0.004). Conclusions CRT improves cardiac function in hypothyroid patients. The ventricular arrhythmic events requiring ICD therapies are associated with baseline TSH level, which might be considered as an important biomarker to stratify the risk of sudden death for patients with heart failure and hypothyroidism.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1471-2261
Relation: http://link.springer.com/article/10.1186/s12872-020-01693-w; https://doaj.org/toc/1471-2261
DOI: 10.1186/s12872-020-01693-w
URL الوصول: https://doaj.org/article/121b1ad996d44f49ad38b64bab67b6e0
رقم الانضمام: edsdoj.121b1ad996d44f49ad38b64bab67b6e0
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:14712261
DOI:10.1186/s12872-020-01693-w